Safety and immunogenicity of cell culture-derived A/H3N2 variant influenza vaccines: A phase i randomized, observer-blind, dose-ranging study

Journal of Infectious Diseases

Volumn 212, Issue 1, 2015, Pages 72-80

  Johnson, Casey ^a   Hohenboken, Matthew ^b   Poling, Terry ^c   Jaehnig, Peter ^d   Kanesa Thasan, Niranjan ^b  

^a JRW Bioremediation LLC   (United States)

^b Novartis Vaccines and Diagnostics Inc   (United States)

^c Agronomic Services   (United States)

^d Novartis Vaccines and Diagnostics GmbH   (Germany)

Author keywords

A H3N2 variant; cell culture derived; immunogenicity; influenza; safety; vaccine; virus

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; MIFAMURTIDE; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ADJUVANT THERAPY; ADULT; AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA A (H3N2); INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LOSS OF APPETITE; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NORMAL HUMAN; OBSERVATIONAL STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; VOMITING; ADOLESCENT; BLOOD; CLINICAL TRIAL; CULTURE TECHNIQUE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INFLUENZA A VIRUS (H3N2); INFLUENZA VIRUS A H3N2; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; PHARMACEUTICS; PRESCHOOL CHILD; PROCEDURES; SINGLE BLIND PROCEDURE; VERY ELDERLY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CELL CULTURE TECHNIQUES; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; SINGLE-BLIND METHOD; SQUALENE; TECHNOLOGY, PHARMACEUTICAL; YOUNG ADULT;

EID: 84936751055     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu826     Document Type: Article

References (28)

1. Centers for Disease Control and Prevention (CDC). Influenza A (H3N2) variant virus. http://www.cdc.gov/flu/swineflu/h3n2v-cases. htm. Accessed March 2014.
2. Centers for Disease Control and Prevention (CDC). Case count: detected U.S. human infections with H3N2v by state since August 2011. http://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm. Accessed March 2014.
3. Jhung MA, Epperson S, Biggerstaff M, et al. Outbreak of variant influenza A(H3N2) virus in the United States. Clin Infect Dis 2013; 57:1703-12.
4. Gray GC, Cao WC. Editorial commentary: variant influenza A(H3N2) virus: looking through a glass, darkly. Clin Infect Dis 2013; 57:1713-4.
5. Pearce MB, Jayaraman A, Pappas C, et al. Pathogenesis and transmission of swine origin A(H3N2)v influenza viruses in ferrets. Proc Natl Acad Sci USA 2012; 109:3944-9.
6. Keitel W, Groth N, Lattanzi M, et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010; 28:840-8.
7. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004; 4:499-509.
8. European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). 1997.
9. Center for Biologics Evaluation and Research (CBER). Food and Drug Administration (FDA). Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. 2009.
10. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35.
11. Manzoli L, Ioannidis JP, Flacco ME, De Vito C, Villari P. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Hum Vaccin Immunother 2012; 8:851-62.
12. Manzoli L, De Vito C, Salanti G, D'Addario M, Villari P, Ioannidis JP. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLOS One 2011; 6:e24384.
13. Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R. Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. Influenza Other Respir Viruses 2011; 5:299-305.
14. Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G. A randomized clinical trial to identify the optimal antigen and MF59 ((R)) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Vaccine 2012; 30:3470-7.
15. Ruiz-Aragon J, Grande Tejada AM, Marquez-Pelaez S, Molina Linde JM, Yang R. [Assessment of the MF59-adjuvanted pandemic influenza A/H1N1 vaccine. Systematic review of literature]. An Pediatr (Barc) 2013; 79:208-17.
16. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3:1-9.
17. Waalen K, Kilander A, Dudman SG, Ramos-Ocao R, Hungnes O. Agedependent prevalence of antibodies cross-reactive to the influenza A (H3N2) variant virus in sera collected in Norway in 2011. Euro Surveill 2012; 17:1-5.
18. Skowronski DM, Janjua NZ, De Serres G, et al. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis 2012; 206:1852-61.
19. Centers for Disease Control and Prevention (CDC). Antibodies crossreactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies-United States. MMWR Morb Mortal Wkly Rep 2012; 61:237-41.
20. Shu B, Garten R, Emery S, et al. Genetic analysis and antigenic characterization of swine origin influenza viruses isolated from humans in the United States, 1990-2010. Virology 2012; 422:151-60.
21. Webby RJ, Swenson SL, Krauss SL, Gerrish PJ, Goyal SM, Webster RG. Evolution of swine H3N2 influenza viruses in the United States. J Virol 2000; 74:8243-51.
22. Gambhir M, Swerdlow DL, Finelli L, et al. Multiple contributory factors to the age distribution of disease cases: a modeling study in the context of influenza A(H3N2v). Clin Infect Dis 2013; 57(suppl 1):S23-7.
23. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375:1100-8.
24. Hardelid P, Andrews NJ, Hoschler K, et al. Assessment of baseline agespecific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. Health Technol Assess 2010; 14:115-92.
25. Faenzi E, Zedda L, Bardelli M, et al. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. Vaccine 2012; 30: 4086-94.
26. Liang XF, Li L, Liu DW, et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N Engl J Med 2011; 364:638-47.
27. Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010; 28:7248-55.
28. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007; 6:699-710.